Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX).
Skin toxicity
cetuximab
cytokines
inflammatory factors
monoclonal antibodies
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
29 11 2020
29 11 2020
Historique:
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
29
7
2021
Statut:
epublish
Résumé
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody is a standard treatment of metastatic colorectal cancer (mCRC) and its most common adverse effect is a papulopustular acneiform rash. The aim of the CUTACETUX study was to characterize the skin inflammatory response associated with this rash and its relation to treatment efficacy. This prospective study included patients with mCRC treated with first-line chemotherapy plus cetuximab. Patients underwent skin biopsies before the initiation of cetuximab (D0) and before the third infusion (D28), one in a rash zone and one in an unaffected zone. Expression of Th17-related cytokines (IL-17A, IL-21, IL-22), antimicrobial peptides (S100A7 and BD-2), innate response-related cytokines (IL-1β, IL-6, TNF-α and OSM), T-reg-related cytokines (IL-10 and TGF-β), Th1-related cytokine (IFN-γ), Th2-related cytokine (IL-4), Thymic stromal lymphopoietin and keratinocyte-derived cytokines (IL-8, IL-23 and CCL20) were determined by RT-PCR. Twenty-seven patients were included. Levels of most of the cytokines increased at D28 in the rash zone compared to D0. No significant association was observed between variations of cytokines levels and treatment response in the rash zone and only the increase of IL-4 (
Identifiants
pubmed: 33299659
doi: 10.1080/2162402X.2020.1848058
pii: 1848058
pmc: PMC7714491
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1848058Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Front Immunol. 2019 Dec 03;10:2847
pubmed: 31849996
Am J Pathol. 2003 Jul;163(1):303-12
pubmed: 12819035
J Immunol. 2010 Mar 24;184(9):5263-5270
pubmed: 20335534
Int J Cancer. 2009 Jun 1;124(11):2589-96
pubmed: 19208382
Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):94-102
pubmed: 29808807
Arch Immunol Ther Exp (Warsz). 2009 Sep-Oct;57(5):345-54
pubmed: 19688185
Front Immunol. 2019 Jul 26;10:1764
pubmed: 31402919
J Clin Oncol. 2002 Jan 1;20(1):110-24
pubmed: 11773160
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
Mini Rev Med Chem. 2012 Jan;12(1):44-52
pubmed: 22070692
Oral Oncol. 2011 Oct;47(10):961-6
pubmed: 21889392
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Gastroenterology. 2018 Dec;155(6):1706-1715
pubmed: 30218667
J Am Acad Dermatol. 2006 Feb;54(2):258-65
pubmed: 16443056
Sci Transl Med. 2019 Dec 11;11(522):
pubmed: 31826981
Cancer. 2001 Sep 1;92(5):1331-46
pubmed: 11571750
J Immunol. 2007 Apr 1;178(7):4615-22
pubmed: 17372020
Nat Rev Cancer. 2006 Oct;6(10):803-12
pubmed: 16990857
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Cancer Treat Rev. 2012 Aug;38(5):451-66
pubmed: 21945823
World J Gastroenterol. 2007 Oct 7;13(37):4996-5002
pubmed: 17854143
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
J Physiol Pharmacol. 2009 Dec;60(4):141-6
pubmed: 20065508
PLoS One. 2014 Jul 10;9(7):e101937
pubmed: 25010647
Oncotarget. 2016 Nov 1;7(44):72167-72183
pubmed: 27708224
Expert Rev Dermatol. 2008 Oct;3(5):525-527
pubmed: 19649143
Sci Transl Med. 2013 Aug 21;5(199):199ra110
pubmed: 23966299
Drugs. 2010 May 28;70(8):949-64
pubmed: 20481653
Oncoimmunology. 2013 Oct 1;2(10):e26333
pubmed: 24251081
J Cancer Res Clin Oncol. 2006 Nov;132(11):719-25
pubmed: 16835747
J Clin Oncol. 2009 Jun 10;27(17):2751-7
pubmed: 19332731
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
pubmed: 7612182
Oncol Lett. 2019 Sep;18(3):2677-2683
pubmed: 31404289
J Clin Oncol. 2005 Aug 1;23(22):5235-46
pubmed: 16051966
N Engl J Med. 2009 Apr 2;360(14):1408-17
pubmed: 19339720
Tumour Biol. 2000 Mar-Apr;21(2):105-15
pubmed: 10686540
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Int J Cancer. 2011 May 1;128(9):2038-49
pubmed: 20648559
J Clin Oncol. 2008 Jan 20;26(3):374-9
pubmed: 18202412
N Engl J Med. 2004 Jul 22;351(4):337-45
pubmed: 15269313
Clin Cancer Res. 2001 Oct;7(10):2958-70
pubmed: 11595683
Acta Oncol. 1998;37(3):285-9
pubmed: 9677101
Oncotarget. 2015 Oct 13;6(31):31604-12
pubmed: 26384309
Invest New Drugs. 2006 Mar;24(2):99-110
pubmed: 16502353
Lung Cancer. 2005 Dec;50(3):393-9
pubmed: 16153743
Eur J Dermatol. 2004 Nov-Dec;14(6):391-9
pubmed: 15564203
J Invest Dermatol. 2008 Jun;128(6):1365-74
pubmed: 18049451
J Clin Oncol. 2010 Mar 10;28(8):1351-7
pubmed: 20142600